Quick Answer
HALOZYME THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $133.82 million for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed an increase of +15.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), HALOZYME THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has grown by 110.0%.
- Historical annual values: Fiscal year 2025: $133.82 million | Fiscal year 2024: $115.85 million | Fiscal year 2023: $118.37 million | Fiscal year 2022: $234.20 million | Fiscal year 2021: $118.72 million | Fiscal year 2020: $147.70 million | Fiscal year 2019: $120.18 million | Fiscal year 2018: $57.94 million | Fiscal year 2017: $168.74 million | Fiscal year 2016: $66.76 million | Fiscal year 2015: $43.29 million | Fiscal year 2014: $61.39 million | Fiscal year 2013: $27.36 million | Fiscal year 2012: $99.50 million | Fiscal year 2011: $52.38 million | Fiscal year 2010: $82.76 million | Fiscal year 2009: $67.46 million | Fiscal year 2008: $63.72 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: